Overview of Codeine Linctus

Quick Facts

Property	Description
Active ingredient	Codeine phosphate
Form	Linctus (Oral Solution/Syrup)
Pharmacological class	Narcotic Antitussive
Common use	Symptomatic relief of dry cough
Origin	Semi-synthetic opioid derivative

What Type of Medicine is Codeine Linctus?

Codeine Linctus is a pharmaceutical preparation that is clinically recognized as an antitussive, a specific class of medication designed to suppress or reduce the frequency of coughing. The primary active component is Codeine, typically incorporated as Codeine phosphate, which establishes the drug’s identity as a narcotic antitussive with a centrally mediated effect. This central mechanism provides targeted symptomatic relief. The product is supplied as a linctus, which is a liquid oral solution or syrup specifically formulated to be swallowed slowly for oral administration.

Codeine Linctus Composition and Origin

The composition relies on the single-ingredient active component, Codeine phosphate. As a semi-synthetic opioid derivative, Codeine is chemically synthesized from Morphine, an alkaloid naturally found in the opium poppy. This distinct origin differentiates it from purely synthetic cough suppressants. The liquid preparation utilizes an aqueous or sugar-based vehicle (syrup) alongside excipients; this specific liquid form is often preferred by patients who find swallowing solid oral tablets difficult. Codeine is pharmacologically classified as a centrally acting cough suppressant, a designation that defines its primary pharmacological property.

What is the Purpose of a Narcotic Antitussive?

The essential purpose of Codeine Linctus is to provide symptomatic relief for a persistent, dry, non-productive cough—a cough that is often irritating and provides no therapeutic benefit in clearing the airways. The medication achieves this by exerting a central action on the medulla oblongata in the brain, the regulatory control point for the involuntary cough reflex. This action minimizes the frequency and intensity of the cough impulse, thereby helping to reduce the overall disruption and exhaustion caused by chronic, hacking coughs.

Regulatory References

NIH Drug Record: Codeine

What side effects are possible with Codeine Linctus?

Possible side effects and safety information

This section outlines the officially documented adverse reactions and safety characteristics of Codeine Linctus, as classified by government regulatory authorities.

Adverse Reaction Scope

The medicine's safety profile is defined by effects primarily affecting the Nervous System and the Gastrointestinal System. Regulatory documents classify common adverse reactions, which include drowsiness, lightheadedness, dizziness, sedation, nausea, vomiting, and constipation.

Category	Description (Regulatory Summary)
Serious Adverse Risks	Potential for life-threatening respiratory depression, even at recommended doses. Risk of drug dependence (addiction) with prolonged use, and Circulatory Depression in severe cases.
Population Restrictions	Contraindicated in children under 12 years of age for any use. Contraindicated for individuals known to be ultra-rapid metabolisers of codeine and for breastfeeding women due to toxicity risk.

Safety Patterns and Constraints

Official labeling indicates that the risk of severe respiratory depression is highest during the initiation of therapy or following a dose increase. Conversely, physical drug dependence and tolerance are specifically associated with prolonged use of the medicine.

Use is contraindicated in patients with pre-existing conditions such as significant respiratory depression, severe asthma, severe hepatic dysfunction, or known paralytic ileus.

These official classifications define the strict boundaries and necessary precautions required for the medicine's authorization, separating expected effects from serious risks.

Overdose and Emergency Response

The official regulatory profile for Codeine Linctus overdose is characterized by severe Central Nervous System (CNS) and Respiratory Depression. Documented clinical manifestations of overdose include slow, shallow, or difficult breathing that may stop entirely, profound loss of consciousness leading to coma or stupor, and the presence of pinpoint pupils. Other documented signs may involve cyanosis (bluish coloring of the lips and skin), a limp body, and a slow or weak heartbeat. This acute toxicological state is associated with severe, life-threatening outcomes, including respiratory failure and death.

Regulatory guidance requires immediate medical attention upon suspicion of overdose. Patients exhibiting signs of severe toxicity must have emergency services contacted immediately. Official management procedures are centered on pharmacological reversal using the opioid antagonist Naloxone to restore respiratory function. Treatment also involves symptomatic and supportive measures, such as providing breathing support (e.g., oxygen or mechanical ventilation) and continuous monitoring of vital signs until the toxic effects have subsided. Regulators specifically note that accidental ingestion of even one dose can be fatal to children and caution that the elderly and ultra-rapid metabolizers face increased risk of life-threatening respiratory depression.

Therapeutic Uses of Codeine Linctus

What Codeine Linctus Treats: Main Uses and Benefits

Codeine Linctus is commonly used to help with symptoms related to physical discomfort, applied in scenarios where additional symptomatic support may be needed. This medicine is commonly used for managing a dry, non-productive cough in adults, which may be described as an irritating 'tickle' that won't go away. The medication is generally associated with the management of dry cough in adults, an approach that is relevant when supportive symptom management is appropriate for easing difficult episodes.

Therapeutic Benefits

A key patient-oriented benefit is the contribution to improved comfort, particularly at night, which assists with maintaining functional stability. The medication supports patients during difficult episodes by easing the distress caused by frequent, uncontrolled coughing fits that interfere with daily functioning and rest. This medicine is commonly used across conditions characterized by periods of heightened symptoms, applied when appropriate for managing pronounced symptoms.

“This medicine helps to ease the overall symptom burden when symptoms become temporarily overwhelming.”

Quick Fact: Relief for Persistent, Irritating Dry Cough The medicine is relevant for easing symptoms that create noticeable physiological strain.

Regulatory References

UK Government (Medicines and Healthcare products Regulatory Agency - MHRA)

Eligibility and Restrictions for Use

Who Can and Cannot Use Codeine Linctus?

Eligibility to use Codeine Linctus is strictly controlled by regulatory bodies due to the risk of respiratory depression and opioid toxicity, particularly in certain populations. The medicine is primarily indicated for the treatment of dry, non-productive cough in adults.

Classification	Eligibility Status (Official Regulatory Statement)
Absolute Contraindication	Children under 12 years of age must not use this medicine. It is also prohibited for breastfeeding women and individuals known to be CYP2D6 ultra-rapid metabolisers of codeine, regardless of age.
Restricted Use	Adolescents aged 12 to 18 years with compromised respiratory function (e.g., severe respiratory conditions) are not recommended to use the medicine. It is also contraindicated for all patients under 18 following tonsillectomy or adenoidectomy.
Conditional Use	Use requires caution in the elderly and in patients with severe renal or hepatic impairment, where avoidance is often recommended. Use during pregnancy is generally advised against, especially during the first trimester.

These official eligibility rules establish mandatory exclusions for specific age groups and those with metabolic or clinical vulnerabilities. The restrictions are designed to prevent the rapid, unpredictable conversion of codeine to morphine, which can lead to life-threatening respiratory events in non-eligible patient groups.

What should I know about interactions with other medicines?

Codeine Linctus Interactions with other medicines and products

Codeine Linctus can interact with numerous medicines, primarily through enhanced central nervous system (CNS) effects and altered metabolism. These interactions may result in serious adverse reactions.

Risk of CNS Depression

Co-administration with other CNS depressants increases the risk of excessive sedation, respiratory depression, and hypotension. This includes: Alcohol, general anaesthetics, antipsychotics, anxiolytics and hypnotics (like benzodiazepines), and certain antihistamines with sedative properties. Concomitant use with Sodium oxybate and Tricyclic antidepressants also requires caution.

Interactions Affecting Codeine Metabolism

Codeine is a prodrug metabolized to its active form, morphine, primarily by the liver enzyme CYP2D6. Medicines that affect this pathway can alter codeine's efficacy or safety profile:

CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine, quinidine) can decrease the formation of morphine, potentially leading to reduced therapeutic effect.
CYP3A4 Inhibitors may increase metabolism via the CYP2D6 pathway, potentially increasing morphine levels.
CYP3A4 Inducers (e.g., rifampicin, carbamazepine) can lower the levels of active morphine.

Contraindicated and Restrictive Combinations

Codeine use is contraindicated in patients receiving Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping them, due to the risk of severe adverse effects. Codeine also antagonizes the effects of gastrointestinal motility agents such as metoclopramide. It can also delay the absorption of some anti-arrhythmic medicines, such as mexiletine. Patients who are CYP2D6 ultra-rapid metabolizers are at increased risk of serious adverse reactions from rapid morphine conversion and should not use codeine.

Mechanism of Action

Codeine is pharmacologically classified as a prodrug and is metabolized primarily by the hepatic CYP2D6 enzyme in the liver through an O-demethylation process. This generates the active metabolite, morphine, which subsequently exerts its biological effect. The active metabolite functions as a full agonist at the mu-opioid receptors (mu-OR). These mu-OR are G-protein coupled receptors (GPCRs) found extensively throughout the central nervous system (CNS). The agonism of the mu-OR modulates neurotransmitter release, which in turn inhibits the afferent signaling pathways responsible for initiating the cough reflex. Activation of these receptors increases the membrane conductance of potassium ions, leading to hyperpolarization and a decrease in neuronal excitability. This entire mechanistic cascade focuses on the medullary cough center in the brainstem. The resulting mu-OR binding decreases the excitability of key neuronal circuits within this center, leading to a diminished cough response. This specific pathway engagement is the mechanistic foundation by which Codeine linctus exerts its biological action.

Dosage and Administration Information

Codeine Linctus is an oral solution formulated for administration by mouth, with instructions detailing the volume, frequency, and duration of use. The standard strength is typically 15 mg of Codeine Phosphate per 5 mL dose.

Dosing and Administration

Usage Entity	Instruction
Administration Route	Oral, as a liquid solution (linctus).
Adult Single Dose	5 mL to 10 mL.
Dosing Frequency	Intermittent use, repeated every 4 to 6 hours if required.
Maximum Use	Not more than 4 doses in any 24-hour period.
Duration Constraint	Intended for short-term use only, not to exceed 3 consecutive days without medical review.

Administration Rules by Population

The instructions define use for specific patient populations, emphasizing dose reduction or contraindication where necessary:

Pediatric Patients: Codeine is contraindicated for use in children under 12 years of age for cough and cold symptoms. Use in adolescents aged 12 to 18 years is not recommended if they have compromised respiratory function.
Older Adults: A reduced dose is recommended for older or debilitated patients.
Hepatic or Renal Impairment: Dose reduction is usually necessary for patients with impaired liver or kidney function.

When taking the linctus, an accurate measuring device must be used to ensure the correct volume is administered. If a dose is missed, standard practice indicates to skip the missed dose and take the next dose at the regular time; a double dose should not be taken to compensate. These domains define the standardized protocol for the medicine's use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase I and II Trials: Clinical Assessment and Early Findings

Early research focused on investigating a dosing range and understanding how the drug is processed by the body. Initial trials examined the pharmacokinetic profile and overall tolerability.

Studies investigated whether administration was associated with early changes in participant reports, and evaluated the change in pain symptoms. These preliminary findings provided data used in subsequent assessments of dosage for later, larger studies.
Research has examined whether patient outcomes were affected in small groups of participants over a short period. Results from these early trials were used to plan the design of later Phase III studies.

Phase III Trials: Clinical Study Design and Follow-up

Phase III trials involved larger participant groups to further evaluate the treatment in a controlled setting.

One study investigated the use of this treatment in adults and tracked potential side effects over a six-month period.
Studies explored a relationship between the treatment and changes in symptom severity when compared to a placebo.
Research evaluated the change in absorption when the combination was used compared to when components were administered separately.

Post-Marketing Surveillance and Ongoing Research

Ongoing research continues to monitor the long-term use and safety profile of the medication in the general population.

Some studies investigated dosing schedules, including administration before bedtime, to assess potential differences in patient experience.
Studies compared clinical outcomes related to this drug to those of other treatments in various populations, with findings reported in medical literature.
Early studies indicated an initial link between this treatment and potential changes in sleep patterns; follow-up studies are exploring this observation.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Codeine Linctus (FAQ)

Q: How quickly does Codeine Linctus start working?

According to official product information, the effect of Codeine Linctus typically begins relatively quickly after administration. Regulatory data indicates that the onset of action following oral administration is usually within 30 to 45 minutes.

Q: How long does the effect of Codeine Linctus last?

Information from regulatory sources indicates the duration of the effect for a single dose of Codeine Linctus is approximately 4 hours.

Q: Can Codeine Linctus be taken with paracetamol?

Official guidance supports that codeine is often administered in combination with paracetamol for symptomatic relief. Regulatory information is consistent with concurrent use in regulatory contexts.

Q: Can Codeine Linctus be taken with ibuprofen?

Official information indicates that codeine can be used in combination with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) like ibuprofen. This combination is supported for symptomatic relief in patient information.

Q: Is it safe to drive after taking Codeine Linctus?

Regulatory documents include a strong warning that this medicine can impair cognitive function and affect a person's ability to drive safely. Official documentation notes that the use of this medicine is associated with impaired ability to drive or operate machinery.

Q: What are the most commonly reported side effects of Codeine Linctus?

Officially documented common adverse reactions often relate to the nervous and gastrointestinal systems. These include effects like drowsiness, lightheadedness, dizziness, sedation, nausea, vomiting, and constipation.

Q: Is it okay to drink alcohol while taking Codeine Linctus?

Regulatory product information notes that co-administration with alcohol can enhance the sedative and respiratory depressive effects of codeine. This combination may increase the risk of excessive drowsiness and breathing problems.

Q: What should I avoid eating or drinking while using Codeine Linctus?

Official warnings primarily address co-administration with alcohol due to the enhanced CNS depressant effects. Some health guidance also suggests that herbs high in tannins may interfere with the medicine's absorption.

Q: Is there a risk of breathing problems with Codeine Linctus?

Yes, regulatory documents warn of the potential for serious side effects, including breathing problems (respiratory depression). This risk is officially noted to be highest during the initial phase of therapy or following a dose increase.

Q: Is Codeine Linctus only available by prescription?

While historically available over-the-counter in some areas, regulatory bodies in many regions have increasingly moved to classify codeine linctus as a prescription-only medicine (POM). This global regulatory trend is intended to help minimize the risks of misuse and dependence.

Q: Can I buy Codeine Linctus over the counter in some places?

Regulatory classification varies by country. Although some regions may allow over-the-counter sales, there is a global regulatory trend toward reclassifying codeine linctus as a prescription-only medicine to increase patient safety control.

Q: Does Codeine Linctus affect fertility?

Official information states that there is no evidence that short-term use at normal doses reduces fertility in men or women. This information is found within the full regulatory documents.

Q: Is Codeine Linctus a controlled substance?

Yes, due to its opioid nature and potential for misuse, Codeine is classified by intergovernmental bodies and national authorities as a controlled substance. It is typically listed under the UN Narcotic Schedules (e.g., Schedule II or III).

Q: How is Codeine Linctus classified by safety organizations?

Codeine Linctus is classified as a narcotic antitussive with a centrally mediated effect. It is also listed under the UN Narcotic Schedules due to its opioid origin and potential for dependence.

Q: Can I take Codeine Linctus if I have asthma?

Official labeling states the medicine is contraindicated (should not be used) in patients with uncontrolled or partly controlled asthma due to the risk of respiratory depression.

Q: Are there any known interactions between Codeine Linctus and herbal supplements?

Regulatory guidance indicates that herbal remedies and supplements are not tested for interactions with prescription medicines in the same way. Some sources note that high-tannin herbs may potentially interfere with absorption.

Q: Why is the maximum duration of use for Codeine Linctus usually limited?

The duration of use is generally limited to 3 consecutive days or less. This limitation is in place because prolonged use carries a known risk of developing drug tolerance and dependence (addiction), as stated in regulatory safety updates.

Q: Can I take Codeine Linctus if I have kidney problems?

Regulatory information indicates that use requires caution if a patient has kidney problems. A dose reduction is usually necessary for patients with impaired kidney function to minimize the risk of adverse effects.

Q: Can I take Codeine Linctus if I have liver problems?

The medicine is contraindicated (prohibited) in patients with severe hepatic dysfunction (severe liver problems). Use with less severe liver impairment generally requires dose reduction to avoid the risk of toxicity.

Q: Does Codeine Linctus affect blood pressure?

Regulatory adverse effect lists include the potential for hypotension (low blood pressure). This effect can be enhanced if the medicine is used concurrently with other CNS depressants, as stated in the product safety profile.

Q: Are there specific warnings about Codeine Linctus for rapid metabolizers?

Yes, official documents state the medicine is contraindicated for individuals known to be CYP2D6 ultra-rapid metabolizers. This genetic trait causes the body to convert codeine to morphine much faster than normal, leading to higher-than-expected levels of the active drug and increasing the risk of opioid toxicity.

Q: Can I take Codeine Linctus on an empty stomach?

Regulatory information addresses administration relative to food. Information from official sources indicates the medicine may be taken with or without food. Taking it with food may be suggested if a patient experiences an upset stomach.

Q: What is the risk of overdose with Codeine Linctus?

An overdose can be life-threatening and may cause severe central nervous system (CNS) symptoms. These include slow or shallow breathing (respiratory depression), confusion, loss of consciousness, and pin-point pupils, as detailed in regulatory documents.

Q: Does Codeine Linctus interact with medicines for depression or anxiety?

Yes, official interaction summaries state that the depressant effects of codeine may be enhanced by tricyclic antidepressants. Concurrent use with other anxiolytics (anti-anxiety medicines) or hypnotics may also increase sedative effects.

How should Codeine Linctus be stored and disposed of?

How to Store and Dispose of Codeine Linctus

Codeine Linctus must be stored according to official regulatory specifications to maintain its stability and effectiveness, focusing on temperature, security, and proper disposal.

Official Storage Requirements

Store the product in its original container, ensuring it is kept tightly closed. The required temperature is below 25, C; the medicine must be protected from heat and moisture, meaning storage in a bathroom or near a sink is prohibited. Due to its classification, it is mandatory to store Codeine Linctus in a locked cabinet and out of the sight and reach of children at all times.

Official Disposal Instructions

Disposal must adhere to pharmaceutical waste guidelines. The unused or expired liquid must not be disposed of via household refuse or poured down the drain. For proper disposal, the product must be returned to a pharmacist or taken to a local drug take-back collection point.

Codeine Linctus